Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Russell 2000 BuyWrite ETF (NY:IWMW)

39.89 -0.20 (-0.50%)
Streaming Delayed Price Updated: 11:54 AM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Russell 2000 BuyWrite ETF

< Previous 1 2 3 4 5 Next >
News headline image
ALT Stock Rallies 4% — What Does Retail Think? ↗
Earlier this month, Altimmune said the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pemvidutide for the treatment of patients with metabolic... 
Via Stocktwits
Bumble Chief Product Officer Reportedly Exits Amid Dating Platform’s ‘Return To Growth’ Efforts ↗
Via Stocktwits
News headline image
BigBear.ai Shares Tumble 8% Ahead Of Crucial Shareholder Vote Deadline On Increasing Authorized Shares ↗
The company wants its investors to approve an amendment for increasing its authorized common shares from 500 million to 1 billion shares. 
Via Stocktwits
Topics Artificial Intelligence
VITL Shares Slip 6% On Health Concerns Around Eggs: Analyst Dismisses ‘Misleading’ Information, Reiterates ‘Buy’ Rating ↗
Via Stocktwits
News headline image
CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think? ↗
The FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday. 
Via Stocktwits
USA Rare Earth Rallies More than 11% - What’s Driving The Optimism? ↗
Via Stocktwits
IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing ↗
Via Stocktwits
IBRX Stock Continues Rally — What’s Driving The Optimism Today? ↗
Via Stocktwits
Bakkt Stock Rallies Nearly 20% - What’s Behind The Move? ↗
Via Stocktwits
News headline image
TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026 ↗
The company expects total revenue for full year 2025 to be about $616 million, including $594 million from sales of its Briumvi in the U.S. 
Via Stocktwits
Topics Artificial Intelligence
SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off? ↗
Via Stocktwits
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March ↗
Via Stocktwits
News headline image
KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart ↗
Ekterly is the first and only oral on-demand treatment for HAE, KalVista said, setting it apart from other on-demand HAE treatment options approved in the U.S. 
Via Stocktwits
MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026 ↗
Via Stocktwits
News headline image
Ardelyx Stock Is Rallying – What Is Making Retail So Bullish? ↗
The company said it made significant commercial progress in 2025, generating approximately $378 million in product revenue. 
Via Stocktwits
Rumble Rallies After Unveiling Tether-Powered Crypto Wallet – Retail Expects Stock To Surpass The $10 Mark ↗
Via Stocktwits
Zeta Global Shares Rose After It Deepens Collaboration with OpenAI ↗
Via Stocktwits
News headline image
ELVN Stock Shot Up 60% Today – What’s Driving The Rally? ↗
The company reported positive initial data from its ongoing Phase 1b clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia. 
Via Stocktwits
News headline image
Joby Inks $61.5 Million Deal To Acquire Another Ready-To-Use Facility In Ohio As It Eyes Doubling eVTOL Production ↗
The new facility spans more than 700,000 feet and is ready for immediate use, the California-based company said. 
Via Stocktwits
Rigetti Computing Stock Draws Retail Buzz After Quantum Timeline Slips And Insider Sale Surfaces ↗
Via Stocktwits
News headline image
WULF Stock Rises 3% Pre-Market After Keefe More Than Doubles Price Target ↗
Keefe Bruyette upgraded TeraWulf to an ‘Outperform’ rating from ‘Market Perform’, citing its optimism on the company’s high-performance computing transition. 
Via Stocktwits
News headline image
Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer ↗
The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data. 
Via Stocktwits
Topics Supply Chain
News headline image
SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study ↗
The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred. 
Via Stocktwits
Topics Death
News headline image
Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug ↗
The company also announced the pricing of a $20 million registered direct offering. 
Via Stocktwits
News headline image
Why Is UUUU Stock Rising Today? ↗
The company said that its finished uranium production, mined uranium ore production, and uranium concentrate sales for FY 2025 exceeded previously announced guidance. 
Via Stocktwits
Topics Government World Trade
News headline image
Biohaven Stock Slumps After Hours As Failed Depression Study Adds To A Brutal 2025 — Retail Eyes Epilepsy And Obesity Catalysts ↗
The company said that no reduction in depressive symptoms were observed in the BHV-7000 trial over six weeks as compared with placebo. 
Via Stocktwits
News headline image
Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout ↗
The investigational drug EDG-7500 was generally well tolerated in the trial, the company said. 
Via Stocktwits
News headline image
SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About? ↗
Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover. 
Via Stocktwits
News headline image
After A Sharp Rally In 2025, Ramaco Is Doubling Down With $100M Share Buyback ↗
Ramaco’s CEO said that, with $600 million-plus (before fees) in capital raises in the second half of 2025, the firm is well-positioned to pursue opportunities to unlock value and maximize shareholder... 
Via Stocktwits
News headline image
EchoStar’s SpaceX Stake Is Driving UBS, Citi Price Target Revisions ↗
UBS lowered EchoStar’s price target to $125 from $128 while Citi raised the firm’s price target to $111 from $87, according to TheFly. 
Via Stocktwits
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS